Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

324
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
324
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

196
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
196
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

109
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
109
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

161
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
161
Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters00:54

Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters

152
The noncompartmental approach is a widely used method in pharmacokinetics to assess drugs' behaviors in the body. It considers several factors, including clearance, bioavailability, and total volume of distribution.
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's...
152
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

104
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
104

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Convergent increases in serotonin 1B receptor binding following ketamine and electroconvulsive therapy: a multi-centre bayesian re-analysis of PET data.

Molecular psychiatry·2026
Same author

Elevated serotonin 1A receptor binding in borderline personality disorder co-morbid with major depressive episodes appears attributable to major depression alone.

Journal of psychiatric research·2026
Same author

BIVARIATE HIERARCHICAL BAYESIAN MODEL FOR COMBINING SUMMARY MEASURES AND THEIR UNCERTAINTIES FROM MULTIPLE SOURCES.

The annals of applied statistics·2026
Same author

External validation and time-stability analysis of STARE, a blood-free quantification tool for irreversible PET tracers.

bioRxiv : the preprint server for biology·2026
Same author

A reference tissue implementation of Simultaneous Multifactor Bayesian Analysis (SiMBA) of PET time activity curve data.

Imaging neuroscience (Cambridge, Mass.)·2025
Same author

Relationship between cortical thickness and serotonin 1A receptor binding in bipolar disorder.

Translational psychiatry·2025

Related Experiment Video

Updated: Aug 7, 2025

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

32.3K

Multivariate analysis of PET pharmacokinetic parameters improves inferential efficiency.

Granville J Matheson1,2,3, R Todd Ogden4,5

  • 1Department of Psychiatry, Columbia University, New York, NY, 10032, USA. granville.matheson@nyspi.columbia.edu.

EJNMMI Physics
|March 13, 2023
PubMed
Summary

This study introduces Parameters undergoing Multivariate Bayesian Analysis (PuMBA), a novel method that enhances statistical power and precision in positron emission tomography (PET) quantification by utilizing all pharmacokinetic parameters. PuMBA offers more informative conclusions without additional data collection.

Keywords:
Bayesian statisticsPharmacokinetic modellingPositron emission tomographyPowerPrecision

More Related Videos

Intraventricular Drug Delivery and Sampling for Pharmacokinetics and Pharmacodynamics Study
09:18

Intraventricular Drug Delivery and Sampling for Pharmacokinetics and Pharmacodynamics Study

Published on: March 31, 2022

2.7K
Basics of Multivariate Analysis in Neuroimaging Data
06:35

Basics of Multivariate Analysis in Neuroimaging Data

Published on: July 24, 2010

16.9K

Related Experiment Videos

Last Updated: Aug 7, 2025

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

32.3K
Intraventricular Drug Delivery and Sampling for Pharmacokinetics and Pharmacodynamics Study
09:18

Intraventricular Drug Delivery and Sampling for Pharmacokinetics and Pharmacodynamics Study

Published on: March 31, 2022

2.7K
Basics of Multivariate Analysis in Neuroimaging Data
06:35

Basics of Multivariate Analysis in Neuroimaging Data

Published on: July 24, 2010

16.9K

Area of Science:

  • Positron emission tomography (PET) imaging
  • Quantitative analysis in nuclear medicine
  • Statistical modeling in biomedical research

Background:

  • PET quantification typically estimates multiple pharmacokinetic parameters from time activity curves.
  • Conventionally, all but the primary parameter of interest are discarded, potentially losing valuable information.
  • There is a need to leverage all estimated parameters for more robust statistical analyses.

Purpose of the Study:

  • To develop and evaluate a novel Bayesian approach, Parameters undergoing Multivariate Bayesian Analysis (PuMBA), for analyzing pharmacokinetic parameters in PET.
  • To demonstrate that incorporating all estimated parameters can improve the precision and statistical power of analyses.
  • To provide a method for drawing more informative conclusions from existing PET data without requiring additional measurements.

Main Methods:

  • A hierarchical multifactor multivariate Bayesian approach was applied, analyzing all estimated parameters from all regions simultaneously.
  • The method, termed Parameters undergoing Multivariate Bayesian Analysis (PuMBA), was tested using simulated patient-control studies.
  • Simulations varied radioligands, sample sizes, and measurement error to compare PuMBA against univariate methods regarding precision, statistical power, false positive rate, and bias.

Main Results:

  • PuMBA significantly improved statistical power across all examined applications compared to univariate methods, without increasing false positive rates.
  • The method enhanced the precision of effect size estimation and reduced the variability of these estimates.
  • PuMBA demonstrated performance improvements even with substantial measurement error and showed greater power than conventional analysis of true binding values.

Conclusions:

  • Parameters undergoing Multivariate Bayesian Analysis (PuMBA) enhances the precision and power of statistical analyses in PET data.
  • This approach allows for the investigation of new research questions using both new and previously collected PET datasets.
  • PuMBA holds significant potential to advance the field of PET imaging analysis and interpretation.